Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may have antiarrhythmic effects.
- Arrhythmias are commonly linked to conditions like diabetes and obesity.
- These comorbidities may significantly affect the development and worsening of arrhythmias.
- Activation of GLP-1 receptors is suggested to be associated with potential benefits in arrhythmia management.
- Emerging evidence supports the idea that GLP-1 RAs could influence heart rhythm stability.
Simplified